Voronoi Submits Clinical Trial Plan Amendment for VRN110755 Global Phase 1/2 Study Adding Singapore HSA Approval Request
Voronoi disclosed that it has submitted a clinical trial plan amendment for VRN110755 in global Phase 1/2 study targeting advanced EGFR mutant non-small cell lung cancer to Singapore's HSA, in addition to Taiwan's TFDA and Australia's HREC.
The amendment aims to expand the study from Phase 1a to 1b/2 to evaluate optimal dose and efficacy after safety and early efficacy signals were observed in Phase 1a.
The multicenter trial across North America, Asia, Oceania, and Europe plans to enroll approximately 391 patients over up to 6 years. The statistical probability of final drug approval is about 10%.
[AI Summary]Voronoi expanded the global clinical scope for VRN110755 by submitting a Phase 1/2 amendment, but no capital changes or fundraising occurred, so existing shareholder value is not immediately affected. However, clinical success uncertainty remains high statistically, and potential costs from advancing to next phases could pose medium-to-long-term financial burdens.
KOSDAQ Filing Information
[Correction of Description] Major Management Matters Related To Investment Decision (Application For Approval Of Clinical Trial Plan Change) (Phase 1/2 Clinical Trial Of VRN110755)